Literature DB >> 14616224

Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day.

R H Perlis1, J Alpert, A A Nierenberg, D Mischoulon, A Yeung, J F Rosenbaum, M Fava.   

Abstract

OBJECTIVE: Patients with major depressive disorder often show only partial or no response to antidepressants, necessitating next-step interventions such as dose increase or augmentation. Factors moderating response to these next-step interventions are not well-studied.
METHOD: In this randomized, double-blind investigation of next-step treatments in 101 outpatients who failed to respond to fluoxetine 20 mg for 8 weeks, the impact of depressive course and sociodemographic factors on likelihood of treatment response following dose increase or lithium or desipramine augmentation was examined.
RESULTS: After controlling for depression severity at baseline, current marriage and earlier onset of depression were associated with greater likelihood of response in a logistic regression. Intervention strategy was not predictive of response.
CONCLUSION: Marital status and earlier onset of depression may be clinically useful in predicting outcome following any next-step intervention for treatment resistance, rather than with particular strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616224     DOI: 10.1046/j.0001-690x.2003.00168.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

2.  A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.

Authors:  Antonio Drago; Enrico Cocchi; Concetta Crisafulli; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-07-02       Impact factor: 3.575

Review 3.  Impact of medical comorbid disease on antidepressant treatment of major depressive disorder.

Authors:  Dan V Iosifescu; Bettina Bankier; Maurizio Fava
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

4.  Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients.

Authors:  S Rzezniczek; M Obuchowicz; W Datka; M Siwek; D Dudek; K Kmiotek; K Oved; N Shomron; D Gurwitz; A Pilc
Journal:  Transl Psychiatry       Date:  2016-05-31       Impact factor: 6.222

5.  Citalopram amplifies the influence of living conditions on mood in depressed patients enrolled in the STAR*D study.

Authors:  F Chiarotti; A Viglione; A Giuliani; I Branchi
Journal:  Transl Psychiatry       Date:  2017-03-21       Impact factor: 6.222

6.  Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases.

Authors:  Alessandro Serretti; Raffaella Calati; Osmano Oasi; Diana De Ronchi; Cristina Colombo
Journal:  Ann Gen Psychiatry       Date:  2007-02-07       Impact factor: 3.455

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.